Search results for " administration"

showing 10 items of 4299 documents

Measuring change in health care equity using small-area administrative data – Evidence from the English NHS 2001–2008

2012

This study developed a method for measuring change in socio-economic equity in health care utilisation using small-area level administrative data. Our method provides more detailed information on utilisation than survey data but only examines socio-economic differences between neighbourhoods rather than individuals. The context was the English NHS from 2001 to 2008, a period of accelerated expenditure growth and pro-competition reform. Hospital records for all adults receiving non-emergency hospital care in the English NHS from 2001 to 2008 were aggregated to 32,482 English small areas with mean population about 1500 and combined with other small-area administrative data. Regression models …

AdultPediatricsmedicine.medical_specialtyHealth (social science)PopulationPrevalenceState MedicineHistory and Philosophy of ScienceHealth caremedicineHumansHealthcare DisparitiesState Medicine/organization & administrationeducationSmall-Area Analysiseducation.field_of_studybusiness.industryHealth services researchHospitals/statistics & numerical dataHospital Recordsmedicine.diseaseObesityHospitalsEnglandSocioeconomic FactorsSmall-Area AnalysisHeart failureHealthcare Disparities/trendsRegression AnalysisHealth Services ResearchbusinessRAKidney diseaseDemographySocial Science & Medicine
researchProduct

Beta-adrenergic blocking activity and haemodynamic effects in man of K� 1313, a new beta-adrenergic antagonist

1971

The beta-adrenergic blocking activity and haemodynamic effects of o-[2-hydroxy-3-(isopropylamino)-propoxy]-benzonitril (Ko 1313) have been studied in 22 patients. Antagonism of isoproterenol-induced tachycardia was used as a measure of the beta-adrenergic blocking activity. Ko 1313 1.0 mg had its maximum beta-adrenoceptor blocking effect 5–30 min after intravenous injection. Ko 1313 10.0 mg produced maximum betablockade 1–4 h after oral administration. 1.0 mg Ko 1313 injected intravenously had approximately the same beta-adrenergic blocking effect as 1.0 mg propranolol also given intravenously. After intravenous administration Ko 1313 was 3–4 times as potent as the same dose given orally. A…

AdultTachycardiamedicine.medical_specialtyCardiac outputAdolescentAdrenergic receptorCardiac VolumeAdrenergic beta-AntagonistsAdministration OralBlood Pressure1-PropanolPropranololPharmacologyElectrocardiographyHeart RateOral administrationInternal medicineNitrilesHeart ratemedicineHumansPharmacology (medical)Cardiac OutputPharmacologyBeta-adrenergic blocking agentPropylaminesbusiness.industryHemodynamicsIsoproterenolGeneral MedicineMiddle AgedAmino AlcoholsPropranololDose–response relationshipEndocrinologyInjections IntravenousSympatholyticsVascular Resistancemedicine.symptombusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

A first-in-human study of PDC31 (prostaglandin F2  receptor inhibitor) in primary dysmenorrhea

2014

What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)?The 1 mg/kg/h dose of PDC31 appears to be safe and potentially effective in reducing intrauterine pressure (IUP) and pain associated with excessive uterine contractility when given as a 3-h infusion in patients with PD.PDC31 has previously been shown to reduce the duration and strength of PGF2α-induced contractions in human uterine myometrial strip models and to delay delivery in animal models of preterm labor.This was a prospective, multi-center, dose-escalating first-in-human Phase I study conducted from March 2011 to June 2012. A total of …

AdultVisual analogue scaleUterusPlaceboDrug Administration ScheduleUterine contractionYoung AdultDysmenorrheaPharmacokineticsInfusion ProceduremedicineHumansProspective StudiesAdverse effectDose-Response Relationship Drugbusiness.industryRehabilitationObstetrics and GynecologyTreatment Outcomemedicine.anatomical_structureReproductive MedicineAnesthesiaPharmacodynamicsFemalemedicine.symptomPeptidesbusinessHuman Reproduction
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Topical Issues in Venous Thromboembolism

2010

Despite clear guidelines and the availability of effective treatments, venous thromboembolism (VTE) remains relatively common, particularly in the hospital setting. This paper reviews topical issues in VTE, in terms of treatments, data and guidelines. Existing anticoagulants have several limitations. Bleeding risk is a concern with all anticoagulants. Vitamin K antagonists are the mainstay of oral anticoagulant therapy, but they are limited by the need for frequent monitoring. Unfractionated heparin (UFH) is limited by an inconvenient route of administration (continuous intravenous infusion) and a higher risk of heparin-induced thrombocytopenia and bleeding compared with low molecular weigh…

Adultmedicine.medical_specialtyBlood Loss SurgicalVenographyFondaparinuxRoute of administrationPharmacotherapymedicineHumansPharmacology (medical)DosingChildIntensive care medicineSocieties Medicalmedicine.diagnostic_testbusiness.industryAnticoagulantsVenous ThromboembolismHeparinmedicine.diseaseUnited StatesClinical trialVenous thrombosisClinical AlarmsPractice Guidelines as TopicDrug Monitoringbusinessmedicine.drugDrugs
researchProduct

A Phase II Trial of Mitoxantrone plus Cyclophosphamide and 5-Fluorouracil in Modulation with Levo-Folinate for Advanced Breast Cancer Patients

1995

Advanced breast cancer remains a major clinical problem. Current chemotherapy regimens are able to induce a clinical response in many patients but do not appear to influence significantly patients' survival. The use of new drugs such as mitoxantrone with a predicted lower toxicity and biochemical modulation of 5-fluorouracil with levo-folinate are extensively studied research areas that could combine good therapeutic efficacy with the maintenance of an acceptable quality of life. 34 patients with advanced breast carcinoma were included in the study. Only 4 women had received prior chemotherapy for advanced disease. Treatment plan was: 5-fluorouracil 400 mg/m2 + l-leucovorin 100 mg/m2 days 1…

Adultmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideAgedAntibacterial agentPharmacologyMitoxantroneCardiotoxicityChemotherapyLeukopeniaDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryInfectious DiseasesOncologyFluorouracilToxicityFemaleFluorouracilMitoxantronemedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

2016

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone …

Adultmedicine.medical_specialtyHydrocarbons Fluorinatedintranasal corticosteroidmedicine.drug_classmedicine.medical_treatmentImmunologynasal sprayAnti-asthmatic AgentMedication Adherence03 medical and health sciencesnasal aerosol0302 clinical medicineQuality of lifeNasal AerosolmedicineAnimalsHumansImmunology and AllergyAnti-Asthmatic AgentsChild030223 otorhinolaryngologyintranasal corticosteroidsAsthmaallergic rhinitisbusiness.industryRespiratory diseaseBeclomethasoneNasal Spraysasthmamedicine.diseaseRhinitis AllergicDermatologyBeclomethasone dipropionate hydrofluoroalkaneAerosol Propellants030228 respiratory systemNasal sprayinflammationQuality of LifeCorticosteroidNasal administrationbusinessallergic rhiniti
researchProduct

Cocaine or phenylephrine/lignocaine for nasal fibreoptic intubation?

1996

In order to assess if a mixture of phenylephrine/lignocaine is as effective as cocaine for local analgesia and vasoconstriction during nasal fibreoptic intubation, 99 patients receiving topical nasal analgesia either with cocaine 10% or a mixture of phenylephrine 1% and lignocaine 4% were studied in a randomized double-blind investigation. After topical analgesia a flexible fibreoptic endoscope was advanced through a nostril. Larynx, glottis and trachea were endoscopically sprayed with lignocaine. Following induction of anaesthesia a nasotracheal tube was inserted fibreoptically. Pain intensity and amount of epistaxis during endoscopy were assessed. Blood pressure, heart rate and ECG-ST seg…

Adultmedicine.medical_specialtyLidocainemedicine.drug_classNostrilmedicine.medical_treatmentNosePhenylephrineCocaineDouble-Blind MethodIntubation Intratrachealotorhinolaryngologic diseasesmedicineFiber Optic TechnologyHumansVasoconstrictor AgentsIntubationLocal anesthesiaAnesthetics LocalPhenylephrineAdministration IntranasalNosebusiness.industryLocal anestheticLidocaineEndoscopySurgerymedicine.anatomical_structureAnesthesiology and Pain MedicineAnesthesiaNasal administrationbusinessAnesthesia Localmedicine.drugEuropean Journal of Anaesthesiology
researchProduct